Protocol Ledger

NCT03828019 · Phase III · COMPLETED

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Interventional Phase III clinical trial protocol NCT03828019 sponsored by JHSPH Center for Clinical Trials in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-16 Enrollment: 227 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03828019
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)227 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03828019
Protocol FieldVerified Registry Value
NCT IdentifierNCT03828019
Consolidated Lead SponsorJHSPH Center for Clinical Trials
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment227 participants (ACTUAL)
Registered Start Date2019-09-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI